A real-world observational study to determine effectiveness and safety of H101 in Chinese patients with malignant pleural effusion and ascites (MPE/MA)
Latest Information Update: 08 Dec 2023
At a glance
- Drugs H-101 (Primary) ; Antineoplastics
- Indications Malignant ascites; Malignant pleural effusion
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 08 Dec 2023 New trial record
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress